Beijing, Feb. 5, 2021 —— InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that China National Medical Products Administration (NMPA) has approved the clinical trial of Bruton’s tyrosine kinase (BTK) inhibitor orelabrutinib in combination with R-CHOP for previously untreated patients with mantle cell lymphoma (MCL).

Beijing, Feb. 4, 2021 —— InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today the first subject dosed in clinical trial of pan-FGFR inhibitor ICP-192 in the United States.

The subscription price of HK$14.45 per share represents an 8.32% premium to the average closing price of the five trading days immediately preceding the date of the Subscription Agreements (not including 2 February 2021).

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its Bruton’s tyrosine kinase (BTK) inhibitor orelabrutinib for treatment of mantle cell lymphoma (MCL).

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that its BTK inhibitor orelabrutinib received approval from the China National Medical Products Administration (NMPA) in two indications: the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL), and the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL). Both new drug applications (NDAs) were previously granted priority review by the Center for Drug Evaluation (CDE) of the NMPA.

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today three presentations of the most recent clinical data with orelabrutinib, its BTK inhibitor, at the 62nd American Society of Hematology (ASH) Annual Meeting.

Beijing, Nov. 9, 2020——InnoCare Pharma (HKEX: 09969), a clinical-stage biopharmaceutical company, announced today that the company executives will attend a series of investor conferences to share company’s latest development in November.